Myriad Genetics Inc (MYGN)

Current ratio

Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019
Total current assets US$ in thousands 293,200 291,600 290,300 313,600 265,400 294,300 261,600 274,600 352,300 367,100 427,400 484,800 498,900 538,900 329,200 394,500 331,700 355,200 365,300 329,500
Total current liabilities US$ in thousands 154,300 148,900 146,100 155,900 209,300 221,100 143,300 137,200 129,100 119,700 166,000 204,300 203,200 271,000 149,000 133,700 147,000 113,200 112,400 115,400
Current ratio 1.90 1.96 1.99 2.01 1.27 1.33 1.83 2.00 2.73 3.07 2.57 2.37 2.46 1.99 2.21 2.95 2.26 3.14 3.25 2.86

September 30, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $293,200K ÷ $154,300K
= 1.90

The current ratio of Myriad Genetics Inc has fluctuated over the past few quarters. As of September 30, 2024, the current ratio stands at 1.90, indicating that the company has $1.90 in current assets for every $1 of current liabilities. This ratio has slightly decreased from the previous quarter's ratio of 1.96, but remains within a reasonable range.

Looking back over the past few years, the current ratio has shown variability with highs in the range of 2.95 to 3.25 and lows around 1.27 to 1.33. The current ratio peaked at 3.25 in June 2022 and hit a low of 1.27 in September 2023.

A current ratio above 1 suggests that Myriad Genetics Inc has more than enough current assets to cover its current liabilities, which is positive for short-term liquidity. It is important to monitor the trend of the current ratio over time to ensure the company has the ability to meet its short-term obligations. It may be worthwhile for stakeholders to further investigate the factors contributing to the fluctuations in the current ratio to assess the company's overall liquidity position.


Peer comparison

Sep 30, 2024